135 related articles for article (PubMed ID: 38381686)
21. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
22. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
23. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP; Bain SC; Consoli A; Eliaschewitz FG; Jódar E; Leiter LA; Lingvay I; Rosenstock J; Seufert J; Warren ML; Woo V; Hansen O; Holst AG; Pettersson J; Vilsbøll T;
N Engl J Med; 2016 Nov; 375(19):1834-1844. PubMed ID: 27633186
[TBL] [Abstract][Full Text] [Related]
24. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
25. Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
Cheema MRS; Kumar S
Acta Diabetol; 2023 May; 60(5):715-716. PubMed ID: 36899150
[No Abstract] [Full Text] [Related]
26. Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
Verma S; David JP; Leiter LA; Michelsen MM; Rasmussen S; Bhatt DL
Diabetes Obes Metab; 2023 Aug; 25(8):2388-2392. PubMed ID: 37016488
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
28. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
29. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
Ruder K
JAMA; 2024 Jan; 331(1):9-11. PubMed ID: 38055301
[TBL] [Abstract][Full Text] [Related]
30. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
Martínez-Montoro JI; Picón-César MJ; Generoso-Piñar M; Fernández-Valero A; López-Montalbán Á; Simón-Frapolli VJ; Hernández-Bayo J; Pinzón-Martín JL; Tinahones FJ
J Intern Med; 2024 Jan; 295(1):113-115. PubMed ID: 37902577
[No Abstract] [Full Text] [Related]
31. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
32. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
33. Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.
Harris E
JAMA; 2023 Oct; 330(14):1318. PubMed ID: 37728959
[No Abstract] [Full Text] [Related]
34. Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.
Goldenberg RM; Steen O
Can J Diabetes; 2019 Mar; 43(2):136-145. PubMed ID: 30195966
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
36. Fathoming the Role of Semaglutide in Obesity Therapeutics.
George M; Balachandran K; Jinson J
Clin Ther; 2023 Aug; 45(8):804-805. PubMed ID: 37442659
[No Abstract] [Full Text] [Related]
37. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
39. Once-Weekly Semaglutide in Adolescents with Obesity.
Malozowski S
N Engl J Med; 2023 Mar; 388(12):1145-1146. PubMed ID: 36947475
[No Abstract] [Full Text] [Related]
40. Once-Weekly Semaglutide in Adolescents with Obesity.
Snaith JR; Greenfield JR
N Engl J Med; 2023 Mar; 388(12):1145. PubMed ID: 36947474
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
